Aimoda (Dacomitinib) 15mg*45's | China-Made EGFR TKI | GLT

Generic Information: Aimoda (China-Mainland)

Aimoda is the domestic Chinese brand of dacomitinib, developed and manufactured by Chengdu Easton Biopharmaceuticals Co., Ltd. (成都苑东生物制药股份有限公司). It is approved in China and has passed the generic-drug consistency evaluation (视同通过一致性评价), confirming bioequivalence to the originator product. This listing covers the 15 mg strength in a 45-tablet box, a convenient larger pack for daily therapy.

What Is Aimoda Used For?

Aimoda is used as a first-line, single-agent treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. It is a domestic alternative to the imported originator, giving patients in China — and buyers sourcing from China — a locally manufactured option that meets national quality standards.

How Does Aimoda (Dacomitinib) Work?

Aimoda contains dacomitinib, an irreversible inhibitor of the ErbB family that covalently blocks EGFR, HER2, and HER4. By permanently shutting down these receptors, it stops the signaling cascades that drive EGFR-mutated lung cancer growth. Because it targets more receptors than first-generation EGFR inhibitors, it offers a broader and more durable anti-tumor effect, which is reflected in survival benefits seen in Asian and exon 21 L858R populations.

Indications

Aimoda is indicated for adults with EGFR-mutated, locally advanced or metastatic NSCLC. Specifically, the tumor must carry an EGFR exon 19 deletion or an exon 21 L858R substitution mutation, confirmed by an approved diagnostic test. It is used as monotherapy and is not indicated for patients without these sensitizing mutations.

Dosage

The standard adult dose is 45 mg once daily, taken with or without food. The 15 mg tablets in this 45-tablet pack support either a reduced-dose regimen or a three-times-daily schedule of 15 mg to reach the 45 mg daily total. Take the medicine at the same time each day; if a dose is missed, continue with the next scheduled dose rather than taking two at once. Avoid proton-pump inhibitors during treatment.

Side Effects

Common adverse reactions include diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, weight loss, alopecia, cough, and pruritus. Most are mild to moderate and respond to supportive care and temporary dose adjustment. Patients should report any new or worsening breathing problems promptly, as interstitial lung disease, although rare, is a serious complication that requires permanent discontinuation of the medicine.

Storage

Store Aimoda at a temperature not exceeding 30°C, in a dry place, in the original container, and out of the reach of children. It does not require refrigeration.

Why Choose China-Sourced Aimoda?

As a domestically manufactured dacomitinib that has passed the consistency evaluation, Aimoda offers the same active ingredient as the originator at a more accessible price within China, and it is covered by China's medical insurance as a Category B medicine. For buyers outside China, sourcing Aimoda represents a lower-cost route to a quality-assured dacomitinib product compared with the originator's Western list price.

How to Order

To order Aimoda through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Provide the strength, pack size, and destination country, and we will confirm sourcing, availability, and the export documents you need. We support both institutional purchasers and individual patients.

FAQ

Is Aimoda a generic of dacomitinib? Yes. Aimoda is a domestically produced dacomitinib in China that has passed the generic-drug consistency evaluation, meaning it is bioequivalent to the originator product.

Who makes Aimoda? Aimoda is manufactured by Chengdu Easton Biopharmaceuticals Co., Ltd., a Chinese pharmaceutical company specializing in oncology products.

Is Aimoda covered by insurance in China? Dacomitinib is included in China's national medical insurance drug list as a Category B item, which helps reduce the out-of-pocket cost for eligible patients.